|本期目录/Table of Contents|

[1]詹济玮,蔡柳春,温琼娜,等.布地格福联合噻托溴铵治疗AECOPD的临床分析[J].中华肺部疾病杂志,2024,(05):823-826.[doi:10.3877/cma.j.issn.1674-6902.2024.05.031]
点击复制

布地格福联合噻托溴铵治疗AECOPD的临床分析(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2024年05期
页码:
823-826
栏目:
短篇论著
出版日期:
2024-10-25

文章信息/Info

Title:
-
作者:
詹济玮1; 蔡柳春1; 温琼娜2; 郭石生1; 温春妹2; 温鹤明1
524000 湛江,湛江中心人民医院老年病科1
524000 湛江,湛江中心人民医院呼吸与危重症医学科2
Author(s):
-
关键词:
急性加重期; 肺疾病; 慢性阻塞性;  噻托溴铵;  布地格福;  疗效
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2024.05.031
摘要:
-
Abstract:
-

参考文献/References:

1 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 14(2): 127-141.
2 慢性阻塞性肺疾病中西医结合管理专家共识写作组. 慢性阻塞性肺疾病中西医结合管理专家共识(2023版)[J]. 中国全科医学, 2023, 26(35): 4359-4371.
3 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南(2021年修订版)[J]. 中华结核和呼吸杂志, 2021, 44(3): 170-205.
4 Bourdin A, Molinari N, Ferguson GT, et al. Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: A systematic literature review and network meta-analysis[J]. Adv Ther, 2021, 38(6): 3089-3112.
5 Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells[J]. Respir Investig, 2020, 58(3): 155-168.
6 刘欣欣, 王浩彦, 张曼林, 等. 改良版英国医学研究会呼吸困难量表评分及肺功能测定对慢性阻塞性肺疾病患者运动能力的预测价值研究[J]. 临床内科杂志, 2016, 33(6): 404-406.
7 文富强, 申永春. 基于线粒体动力学的慢性阻塞性肺疾病发病机制与保护策略[J]. 西南医科大学学报, 2022, 45(5): 369-372.
8 Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations[J]. Clin Chest Med, 2020, 41(3): 421-438.
9 Muro S, Kawayama T, Sugiura H, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history[J]. Respir Res, 2024, 25(1): 297.
10 Bafadhel M, RabE KF, Martinez FJ, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on COPD exacerbations, lung function, symptoms, and quality of life across blood eosinophil ranges: A post-hoc analysis of data from ETHOS[J]. Int J Chron Obstruct Pulmon Dis, 2022, 17: 3061-3073.
11 Macleod M, Papi A, Contoli M, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: diagnosis, treatment, prevention and disease impact[J]. Respirology, 2021, 26(6): 532-551.
12 曾省都, 唐晓媛. 噻托溴铵、孟鲁司特联合布地奈德福莫特罗治疗AECOPD临床观察[J]. 药品评价, 2024, 21(4): 493-495.
13 Martinez FJ, Rabe KF, Ferguson GT, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study[J]. Am J Respir Crit Care Med, 2021, 203(5): 553-564.
14 Yu S, Zhang C, Yan Z, et al. Tiotropium bromide attenuates mucus hypersecretion in patients with stable chronic obstructive pulmonary disease[J]. Comput Math Methods Med, 2021, 2021: 1341644.
15 Stolz D, Hermansson E, Ouwens M, et al. Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT[J]. Curr Med Res Opin, 2023, 39(10): 1395-1405.
16 Strange C, Tkacz J, Schinkel J, et al. Exacerbations and real-world outcomes after single-inhaler triple therapy of budesonide/glycopyrrolate/formoterol fumarate, among patients with COPD: Results from the EROS(US)study[J]. Int J Chron Obstruct Pulmon Dis, 2023, 18: 2245-2256.
17 Nigro SC, Sobieraj DM. Budesonide/glycopyrrolate/formoterol fumarate co-suspension metered dose inhaler: A triple therapy for the treatment of chronic obstructive pulmonary disease[J]. Ann Pharmacother, 2022, 56(5): 582-591.
18 Usmani O, Roche N, Wahab E, et al. A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease[J]. Respir Res, 2021, 22(1): 261.
19 方慧慧, 方 明, 黄 娟, 等. 布地格福吸入治疗对COPD患者IL-6、CRP水平及肺功能的影响[J/CD]. 中华肺部疾病杂志(电子版), 2024, 17(1): 91-94.
20 王学锷, 朱运奎, 李超然, 等. AECOPD合并呼吸道病毒感染的病原体分布、血清炎症因子水平变化及临床意义[J]. 海南医学, 2023, 34(5): 676-679.
21 刘 巍, 马青松. 血清IL-6、IL-17水平对AECOPD合并肺部感染的早期诊断价值及病原菌分析[J]. 分子诊断与治疗杂志, 2022, 14(1): 82-85, 90.
22 何 菁, 俞叶夫, 陈能松. AECOPD患者痰培养结果与血清CRP、SAA、PCT水平的相关性研究[J]. 中国基层医药, 2023, 30(2): 161-166.
23 邓梅毓, 郭晓峰, 赵建清, 等. AECOPD患者C5a、IL-6、IL-17与病情严重程度的关系及延续干预对患者生活质量的影响[J]. 贵州医科大学学报, 2023, 48(12): 1545-1550.
24 刘德义, 马胜喜, 赵振波. AECOPD患者血清炎症因子、D-D、FIB、ET-1及sTREM-1的变化及其意义[J]. 中国老年学杂志, 2021, 41(22): 4955-4957.
25 Xiong XF, Zhu M, Wu HX, et al. Immunophenotype in acute exacerbation of chronic obstructive pulmonary disease: a cross-sectional study[J]. Respir Res, 2022, 23(1): 137.
26 陈伟光, 温剑锋. AECOPD患者呼吸道病毒感染的病原菌及炎症因子检测结果分析[J]. 海南医学, 2021, 32(12): 1530-1533.
27 Wang F, Yang B, Qiao J, et al. Serum exosomal microRNA-1258 may as a novel biomarker for the diagnosis of acute exacerbations of chronic obstructive pulmonary disease[J]. Sci Rep, 2023, 13(1): 18332.
28 朱美君, 孙 芳, 涂水余, 等. 噻托溴铵联合布地格福吸入对慢性阻塞性肺疾病急性加重期患者肺功能及血清特异因子的影响[J]. 山西医药杂志, 2023, 52(14): 1083-1086.
29 Portillo EC, Pollack M, Lee I, et al. Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease(COPD)in the United States: the AURA study[J]. Ther Adv Respir Dis, 2023, 17: 17534666231164534.
30 Martinez FJ, Rabe KF, Ferguson GT, et al. Benefits of budesonide/glycopyrrolate/formoterol fumarate(BGF)on symptoms and quality of life in patients with COPD in the ETHOS trial[J]. Respir Med, 2021, 185: 106509.

备注/Memo

备注/Memo:
通信作者: 詹济玮, Email: 419694968@qq.com
更新日期/Last Update: 2024-10-25